Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, employees in more than 60 countries, and more than 11,000 employees worldwide.
Nonclinical Development: Toxicology, Research Products, Analytical Services
• Managed 443 compound development programs (>250 IND/CTA enabling), with over 100 different sponsors, which led to 41 IND/CTA applications in 2009 • Performed best-in-class productivity cycle times: FIA to FIH in 22 weeks • Dedicated Capacity Agreements with several major pharma customers • Greater than 2.5M sq ft of research space
Clinical Development: Clinical Pharmacology, Clinical, Central Labs
• Supported 50% of latest breakthrough cancer treatments • Supported development of the top 25 currently marketed medicines • 70% of clinical programs on or ahead of enrollment timelines • Broad-based, scalable and market-leading, Biomarker capability • 99% of samples received within stability • 145 million laboratory tests; 83,000 investigator sites; 100 countries • Seven Clinical Pharmacology units with ~500 beds
Periapproval & Market Access
• Results-driven reimbursement support for >60% of the biologics market • Designed and managed world’s largest safety registry ever – iPledge • Team of experts dedicated to risk management and Pharmacovigilance • Bi-coastal call center capabilities to deliver patient and physician support